Ovarian Cancer Clinical Trial
— CHIPPIOfficial title:
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.
Status | Recruiting |
Enrollment | 362 |
Est. completion date | August 1, 2028 |
Est. primary completion date | August 1, 2027 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 76 Years |
Eligibility | Inclusion Criteria: Pre-eligibility criteria to be checked before surgery for pre-registration 1. Age =18 years and = 76 years 2. Histologically proven primary epithelial ovarian carcinoma or fallopian tube carcinoma or peritoneal carcinoma (including serous papillary adenocarcinoma, clear-cell carcinoma, mucinous adenocarcinoma and endometrioid carcinoma) 3. Pre-therapeutic FIGO (International Federation of Gynecology and Obstetrics) stage III 4. Patient eligible for 1. Primary Debulking Surgery (PDS) with planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy 2. Or Interval Debulking Surgery (IDS) after neo-adjuvant chemotherapy +/- bevacizumab or other targeted therapy, with or without planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy. In case of neo-adjuvant chemotherapy, surgery should be performed in a time interval of 3 to 5 weeks in case of chemotherapy without bevacizumab, and in a time interval of 4 to 6 weeks if chemotherapy is combined with bevacizumab. The patient remains eligible for the study if surgery is delayed beyond the recommended time interval. 5. WHO (World Health Organization Performance Status) = 2 6. Physical status score ASA (American Society of Anesthesiologists) = 2 7. Adequate bone marrow and renal function, as evidenced by the following tests performed within 7 days prior to surgery: - Absolute Neutrophil Count (ANC) =1,500/mm3 - Platelets =100,000/mm3 - Aspartate aminotransferase (ALT)/ Alanine aminotransferase (ALT) =2.5 × upper limit of normal (ULN) (=5.0 × ULN in case of liver metastases) - Total bilirubin =1.5 × ULN (except in case of Gilbert's disease) - Creatinine clearance = 60 mL/ min 8. Negative serum pregnancy test within 7 days prior to surgery for women of childbearing potential. For non-menopausal women, if no hysterectomy is planned, willing to accept the use of an effective contraceptive regimen during the treatment period and at least 6 months after the end of treatment (surgery or adjuvant chemotherapy) 9. Absence of contraindication to receive the products used in this study (cisplatin and products used in neo-adjuvant/ adjuvant chemotherapy) according to the most recent SmPC (Summary of Product Characteristics) of these products 10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up 11. Signed written informed consent 12. Patient covered by the French or Belgian "Social Security" regime Criteria to be checked per-operatively for confirmation of enrolment and randomization 13. Residual disease after surgery (cytoreduction score CC) CC-0 (no macroscopic residue) or CC-1 (residue < 2.5 mm) 14. Per-operative hemorrhage < 2.5 L 15. Strictly less than 3 digestive resections performed during surgery 16. Diuresis maintained during surgery, without oliguria or anuria (per-operatory diuresis = 0,5 mL/ kg/ h) Exclusion Criteria: 1. Benign disease, borderline disease, non epithelial ovarian carcinoma or carcinosarcoma 2. Cirrhosis 3. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation 4. Auditory impairment 5. Dehydration or intercurrent disease that contraindicates hyperhydration (including cardio-respiratory disease) 6. Other uncontrolled intercurrent disease including, but not limited to: diabetes; hypertension; symptomatic congestive heart or pulmonary failure; renal, hepatic or severe gastrointestinal (associated with diarrhea) chronic disease 7. Any unresolved NCI-CTCAE Grade = 2 toxicity from previous anticancer therapy (excluding alopecia) 8. Concomitant treatment with prophylactic phenytoin 9. Receipt of live attenuated vaccine, including yellow fever vaccine, within 30 days prior to inclusion (and, if patient is enrolled, up to 30 days after the last administration of study treatment) 10. Pregnant or breastfeeding woman 11. Psychiatric illness or social situation that would limit compliance with study requirement, substantially increase the risk of side effects, or compromise the ability of the patient to give written informed consent 12. Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons) 13. Person under guardianship |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques universitaires St-Luc, Institut Roi Albert II | Bruxelles | |
France | Institut de Cancérologie de l'Ouest | Angers | |
France | Institut Bergonié | Bordeaux | |
France | Centre François Baclesse | Caen | |
France | Centre Jean Perrin | Clermont-Ferrand | |
France | Centre Oscar Lambret | Lille | |
France | Hôpital Jeanne de Flandre | Lille | |
France | Institut Paoli Calmettes | Marseille | |
France | ICM-Val d'Aurelle | Montpellier | |
France | Hôpital Européen Georges Pompidou | Paris | |
France | Centre Hospitalier Lyon Sud | Pierre-Bénite | |
France | Centre Henri Becquerel | Rouen | |
France | Clinique Mathilde | Rouen | |
France | Institut de Cancérologie de l'Ouest | Saint-Herblain | |
France | Hôpital de Hautepierre | Strasbourg | |
France | Institut de Cancérologie de Lorraine | Vandœuvre-lès-Nancy | |
France | Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Centre Oscar Lambret |
Belgium, France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease-free Survival (DFS) | The DFS will be measured to assess the efficacy of the combination treatment of surgery and HIPEC or standard care alone. | From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years) | |
Secondary | Overall survival | The overall survival will be measured to assess the efficacy of HIPEC in combination with standard care. | From randomization to first progression, relapse or death from any cause , whichever came first, assessed up to 5 years.. | |
Secondary | Adverse events (AE) | The adverse events (AE) are collected to evaluate the impact of HIPEC on the safety and on the feasibility of adjuvant treatment (if any) is planned after surgery. | Covers the whole treatment duration from Randomization up to the end of treatment (surgery or CT) plus 30 days. | |
Secondary | Q-TWiST | Q-Twist (Quality-adjusted time without symptoms of disease or toxicity) will be calculated from the survival tile (OS and DFS) and AE (adverse events) data. | Over the 5 year surveillance period | |
Secondary | Quality of life of the patient (QLQC30) | European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30) will be used to measure the quality of life of the patients. | Up to 2 years after the end of treatment (every 3 month) | |
Secondary | Quality of life of the patient (QLQOV28) | European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28) will be used to measure the quality of life of the patients. | Up to 2 years after the end of treatment (every 3 month) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |